

Study Number		ARET0321		
NCT #		NCT00554788		
Dataset #		D1		
PMID #		35820112		
Comments: Blanks represent missing data or not applicable for analyses.				
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).				
Variable Number	Variable Name	Type	Label	Notes
1	USI	Character	Patient identifier	
2	Stratum	Character	Stratum	
3	Eligible	Numeric	Eligible for analyses	0 = No, 1 = Yes If yes, patient is included in variable numbers 5 through 37 and in adverse events (D2).
4	Inelig_reason	Character	Ineligibility reason	
5	Country	Character	Country of enrolling institution	
6	Race	Character	Race	
7	Ethnicity	Character	Ethnicity	
8	Sex	Character	Sex	
9	Age_intra_months	Numeric	Age at intraocular diagnosis (months)	
10	Age_extra_months	Numeric	Age at extraocular diagnosis (months)	
11	Intra_extra_days	Numeric	Days from intraocular diagnosis to extraocular diagnosis	
12	Laterality	Character	Laterality	

Study Number		ARET0321		
NCT #		NCT00554788		
Dataset #		D1		
PMID #		35820112		
Comments: Blanks represent missing data or not applicable for analyses.				
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).				
13	Intra_surg	Numeric	Previous treatment of intraocular disease - surgery	0 = No, 1 = Yes
14	Intra_chemo	Numeric	Previous treatment of intraocular disease – chemotherapy	0 = No, 1 = Yes
15	Intra_xrt	Numeric	Previous treatment of intraocular disease – external beam RT	0 = No, 1 = Yes
16	Bone_marrow	Numeric	Sites of metastatic disease – bone marrow	0 = No, 1 = Yes For Stage IVa patients
17	Bone	Numeric	Sites of metastatic disease – bone	0 = No, 1 = Yes For Stage IVa patients
18	Liver	Numeric	Sites of metastatic disease – liver	0 = No, 1 = Yes For Stage IVa patients
19	Other_soft	Numeric	Sites of metastatic disease – other soft-tissue sites	0 = No, 1 = Yes For Stage IVa patients
20	CNS_type	Character	CNS retinoblastoma type	For Stage IVb patients
21	Lepto_type	Character	Leptomeningeal metastasis	For Stage IVb patients
22	Treatments_received	Character	Treatments received	Treatments received on protocol therapy
23	Treatment_induc	Numeric	Received induction	0 = No, 1 = Yes
24	Treatment_cons	Numeric	Received consolidation	0 = No, 1 = Yes

Study Number		ARET0321		
NCT #		NCT00554788		
Dataset #		D1		
PMID #		35820112		
Comments: Blanks represent missing data or not applicable for analyses.				
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).				
25	Treatment_RT	Numeric	Received radiation therapy	0 = No, 1 = Yes
26	SCT_source	Character	Autologous stem-cell source	
27	Induc_resp	Character	Institutional response - induction	CR = Complete response PD = Progressive disease PR = Partial response SD = Stable disease VGPR = Very good partial response Unknown = Unknown
28	Con_resp	Character	Institutional response – consolidation	CR = Complete response PD = Progressive disease PR = Partial response SD = Stable disease VGPR = Very good partial response
29	RT_resp	Character	Institutional response – radiation therapy	CR = Complete response PD = Progressive disease PR = Partial response SD = Stable disease VGPR = Very good partial response

Study Number		ARET0321		
NCT #		NCT00554788		
Dataset #		D1		
PMID #		35820112		
Comments: Blanks represent missing data or not applicable for analyses.				
Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).				
30	EFS_years	Numeric	Event-free survival (years)	Time in years from study enrollment to relapse, second malignancy, or death from any cause. If an EFS event did not occur, time is calculated as years from study enrollment to date of last contact.
31	EFS_ind	Numeric	Event-free survival indicator	0 = Censor, 1 = EFS event
32	First_event_type	Character	First event type	
33	Relapse_site	Character	Relapse site	
34	SMN	Character	Secondary malignancy diagnosis	
35	Cause_of_death	Character	Cause of death	
36	Death_tx_attr	Character	Death attribution to protocol therapy	
37	OS_ind	Numeric	Overall survival indicator	0 = Censor, 1 = OS event
38	OS_years	Numeric	Overall survival (years)	